Objective: To describe the causes of mortality among the HIV-infected in southern India in the era of highly active antiretroviral therapy (HAART).

Methods: Analyses of this patient cohort were conducted using the YRG Centre for AIDS Research and Education HIV Natural History Observational Database. Causes of death were then individually confirmed by patient chart review.

Results: Sixty-nine deaths occurred within the inpatient unit; 25% were female and the median age of the 69 patients was 34 years. Over half of the patients (55%) died within three months of initiating HAART. At the time of enrollment into clinical care, the median CD4 cell count was 64 cells/microl (interquartile range (IQR) 37-134). At the time of initiating HAART, the median CD4 cell count was 58 cells/microl (IQR 31-67) for patients who died within 3 months of initiating HAART and 110 cells/microl (IQR 77-189) for patients who died more than 3 months after initiating HAART. Close to three-fourths of patients (70%) died from an AIDS-defining illness (ADI). The major ADI causes of death included Pneumocystis jiroveci pneumonia (22%), extrapulmonary tuberculosis (19%), CNS toxoplasmosis (12%), and pulmonary tuberculosis (10%). A tenth of patients died from cerebrovascular infarcts. Three patients (4%) died from non-Hodgkin lymphoma.

Conclusions: AIDS-related events continue to be the major source of mortality among the HIV-infected in southern India in the era of HAART. This mortality pattern justifies increased proactive efforts to identify HIV-infected patients and initiate HAART earlier, before patients present to care with advanced immunodeficiency.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2009.03.034DOI Listing

Publication Analysis

Top Keywords

initiating haart
16
patients died
16
mortality hiv-infected
12
southern india
12
months initiating
12
patients
10
hiv-infected patients
8
era highly
8
highly active
8
active antiretroviral
8

Similar Publications

Background: Antiretroviral therapy (ART) restores cellular immunity, significantly reducing AIDS-related mortality and morbidity thus improving the quality of life among People living with HIV (PLHIV). Studies done in several countries show a decline in AIDS defining cancers (ADCs) with the introduction of ART however the increased longevity has led to the increase of Non-AIDS defining cancers (NADCs). The study was aimed at studying the changing spectrum and trends of cancer among Human Immunodeficiency Virus (HIV) patients in southwestern Uganda.

View Article and Find Full Text PDF

Predictors associated with time to default for HIV/AIDS patients under HAART at Debre Tabor Referral Hospital: a Cox regression model.

Sci Rep

January 2025

Department of Statistics, College of Natural and Computational Science, Debre Tabor University, Debre Tabor, Ethiopia.

The human immunodeficiency virus systematically undermines the immune system, which serves as our body's inherent safeguard against diseases. Currently, it is the most serious threat to public health. Ethiopia is among the countries with the highest prevalence of HIV/AIDS.

View Article and Find Full Text PDF

Highly active antiretroviral therapy (HAART) is imperative in managing human immunodeficiency virus (HIV) infections. HAART aims to inhibit viral replication and improve immunity. Antiretroviral therapy has led to significant improvement in CD4-T cell counts and reductions in viral load, leading to improved overall immune function, increased survival, and decreased frequency of opportunistic infections.

View Article and Find Full Text PDF

Purpose: To investigate ocular manifestation of immune reconstitution inflammatory syndrome (IRIS) in human immunodeficiency virus (HIV) patients after starting highly active antiretroviral therapy (HAART) and its relationship to T cell immunity.

Methods: HIV patients with ocular IRIS after HAART were retrospectively reviewed. Clinical presentations with previous opportunistic infection, duration from initiation of HAART to IRIS, blood CD4+, CD8+ T cell count, and HIV RNA copies before HAART and at IRIS were analyzed.

View Article and Find Full Text PDF

Exploring survival rates in HIV-infected Ethiopian children receiving HAART: a retrospective cohort study.

BMJ Paediatr Open

January 2025

Research Center on Global Emerging and Re-emerging Infectious Diseases, Institute of Tropical Disease, Universitas Airlangga, Surabaya, 60115, Indonesia

Background: Studies have shown a high rate of mortality among adults despite the introduction of highly active antiretroviral therapy (HAART). However, long-term outcomes of HAART among children remain poorly documented in Ethiopia. This study aimed to estimate the survival rate and identify associated factors among HIV-infected children on antiretroviral therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!